New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia

Jordaens, Stephanie; Cooksey, Leah; Freire Boullosa, Laurie; Van Tendeloo, Viggo; Smits, Evelien; Mills, Ken I.; Orchard, Kim H.; Guinn, Barbara ann

Abstract

Acute lymphoblastic leukaemia (ALL) in adults is a rare and difficult-to-treat cancer that is characterised by excess lymphoblasts in the bone marrow. Although many patients achieve remission with chemotherapy, relapse rates are high and the associated impact on survival devastating. Most patients receive chemotherapy and for those whose overall fitness supports it, the most effective treatment to date is allogeneic stem cell transplant that can improve overall survival rates in part due to a ‘graft-versus-leukaemia’ effect. However, due to the rarity of this disease, and the availability of mature B-cell antigens on the cell surface, few new cancer antigens have been identified in adult B-ALL that could act as targets to remove residual disease in first remission or provide alternative targets for escape variants if and when current immunotherapy strategies fail. We have used RT-PCR analysis, literature searches, antibody-specific profiling and gene expression microarray analysis to identify and prioritise antigens as novel targets for the treatment of adult B-ALL.

Citation

Jordaens, S., Cooksey, L., Freire Boullosa, L., Van Tendeloo, V., Smits, E., Mills, K. I., …Guinn, B. A. (2020). New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. Cancer Immunology, Immunotherapy, 69(5), 867-877. https://doi.org/10.1007/s00262-020-02484-0

• Journal Article Type: Review
• Acceptance Date: Dec 9, 2019
• Online Publication Date: Jan 22, 2020
• Publication Date: May 1, 2020
• Deposit Date: Jan 23, 2020
• Publicly Available Date: Jan 28, 2020
• Journal: Cancer Immunology, Immunotherapy
• Print ISSN: 0340-7004
• Electronic ISSN: 1432-0851
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 69
• Issue: 5
• Pages: 867-877
• DOI: https://doi.org/10.1007/s00262-020-02484-0
• Keywords: Immunotherapy, tumour antigens, survivin, BMX, B-cell acute lymphocytic leukaemia, PiVAC19
• Public URL: https://hull-repository.worktribe.com/output/3378205
• Publisher URL: https://link.springer.com/article/10.1007/s00262-020-02484-0
• Additional Information: This paper is a Focussed Research Review based on a presentation given at the Nineteenth International Conference on Progress in Vaccination against Cancer (PIVAC 19), held in Athens, Greece, 7th–9th June, 2019. It is part of a Cancer Immunology, Immunotherapy series of PIVAC 19 papers.